Cancer Risk clinical trials

Explore recruiting cancer risk clinical trials.

Recruiting cancer risk studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Risk trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Low dose TamOxifen and LifestylE changes for bReast cANcer prevenTion: a randomized phase II biomarker trial in subjects at increased risk (TOLERANT Study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Cancer Risk trials by city

Cancer Risk in Toronto Cancer Risk in Vancouver Cancer Risk in Montreal Cancer Risk in Calgary Cancer Risk in Edmonton Cancer Risk in Ottawa Cancer Risk in Winnipeg Cancer Risk in Quebec City Cancer Risk in Hamilton Cancer Risk in Kitchener Cancer Risk in London Cancer Risk in Halifax Cancer Risk in New York Cancer Risk in Los Angeles Cancer Risk in Chicago Cancer Risk in Houston

Cancer Risk clinical trials

Recruiting cancer risk studies right now

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

Towards Optimal Treatment for High Risk Prostate Cancer

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Pembrolizumab in High-risk Thyroid Cancer

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.

Also recruiting in Europe

Low dose TamOxifen and LifestylE changes for bReast cANcer prevenTion: a randomized phase II biomarker trial in subjects at increased risk (TOLERANT Study)

Cancer Risk trials by city

Other conditions